Roth Capital Maintains Cytokinetics (CYTK) at 'Buy' Following BENEFIT-ALS Update
Tweet Send to a Friend
Roth Capital maintains its Buy rating and $13 price target on Cytokinetics (Nasdaq: CYTK) after the company provided an important ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
